# Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

> **NCT02636036** · PHASE1 · COMPLETED · sponsor: **Akamis Bio** · enrollment: 51 (actual)

## Conditions studied

- Colorectal Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Epithelial Tumor

## Interventions

- **BIOLOGICAL:** enadenotucirev
- **BIOLOGICAL:** nivolumab

## Key facts

- **NCT ID:** NCT02636036
- **Lead sponsor:** Akamis Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-08
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-11-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636036, "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02636036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*